Tokyo, Apr 8, 2005 (JCN) - Hisamitsu Pharmaceutical and Nippon Shinyaku (TSE: 4516) announced on April 7 that they have entered into a joint development agreement for HFT-290, a drug candidate for the treatment of cancer pain.
The two companies will conduct Phase III clinicalt trials, and co-promote the new product in Japan.
HFT-290 is a fentanyl citrate plaster developed based on Hisamitsu's proprietary technology, Transdermal Drug Delivery System. With a once-a-day dosage, the drug can achieve stable pain control.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Nippon Shinyaku Launches Oligo RNA for Research Reagent
(July 13, 2007)
|
|
|
Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder
(Jan 25, 2007)
|
|
|
Nippon Shinyaku and Roche Terminate NS-220 License Agreement
(Dec 18, 2006)
|
|
|
Bayer Yakuhin Files Anti-cancer Drug Nexavar(R) for the Treatment of Advanced Renal Cell Carcinoma
(June 29, 2006)
|
|
|
Bayer Yakuhin to Transfer Baynas Marketing Rights to Nippon Shinyaku
(Apr 24, 2006)
|
|
|
Nippon Shinyaku, INNOVIVE Pharmaceuticals Conclude Licensing Agreement for NS-187, Drug Candidate for Chronic Myelogenous Leukemia
(Jan 6, 2006)
|
|
|
Nippon Shinyaku Begins Shipping New Ethical Drug Lodocoat Ointment 0.9%
(Aug 23, 2005)
|
|
|
Nippon Shinyaku Now Distributes AMNOLAKE Tablet, Agent for Acute Promyelocytic Leukemia
(June 14, 2005)
|
|
|
Nippon Shinyaku, Jeil-Kirin Pharmaceutical Conclude Licensing Agreement for TRISENOX Injection
(May 23, 2005)
|
|
|
Hisamitsu Pharmaceutical, Nippon Shinyaku Conclude Joint Development Agreement for HFT-290 Cancer Pain Palliative Care Agent
(Apr 8, 2005)
|
|
|
